Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review

Sileny N Han, Anouk Lotgerink, Mina Mhallem Gziri, Kristel Van Calsteren, Myriam Hanssens, Frédéric Amant, Sileny N Han, Anouk Lotgerink, Mina Mhallem Gziri, Kristel Van Calsteren, Myriam Hanssens, Frédéric Amant

Abstract

Background: Recent insights provide support for the treatment of cancer during pregnancy, a coincidence that poses both mother and fetus at risk. Our aim was to critically review studies on the physiologic variations during pregnancy, the most common tumor markers used in diagnosis and follow-up of gynecological cancers.

Methods: We conducted a systematic review of six tumor markers during normal pregnancy: carbohydrate antigen (CA) 15-3 (breast cancer); squamous cell carcinoma antigen (cervical cancer); and CA 125, anti-Müllerian hormone, inhibin B and lactate dehydrogenase (ovarian cancer).

Results: For CA 15-3, 3.3% to 20.0% of all measurements were above the cut-off (maximum 56 U/mL in the third trimester). Squamous cell carcinoma antigen values were above cut-off in 3.1% and 10.5% of the measurements (maximum 4.3 µg/L in the third trimester). Up to 35% of CA 125 levels were above cut-off: levels were highest in the first trimester, with a maximum value up to 550 U/mL. Inhibin B, anti-Müllerian hormone and lactate dehydrogenase levels were not elevated in maternal serum during normal pregnancy.

Conclusion: During normal pregnancy, tumor markers including CA 15.3, squamous cell carcinoma antigen and CA 125 can be elevated; inhibin B, anti-Müllerian hormone and lactate dehydrogenase levels remain below normal cut-off values. Knowledge of physiological variations during pregnancy can be clinically important when managing gynecological cancers in pregnant patients.

Figures

Figure 1
Figure 1
Methodology for literature review.

References

    1. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5:588–599.
    1. Rustin GJ, van der Burg ME, Griffin CL, Guthrie D, Lamont A, Jayson GC, Kristensen G, Mediola C, Coens C, Qian W, Parmar MK, Swart AM. MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–1163. doi: 10.1016/S0140-6736(10)61268-8.
    1. Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, Halaska M, Vergote I, Ottevanger N, Amant F. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28:683–689. doi: 10.1200/JCO.2009.23.2801.
    1. Stensheim H, Moller B, van DT, Fossa SD. Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol. 2009;27:45–51. doi: 10.1200/JCO.2009.23.8683.
    1. Stensheim H, Cvancarova M, Moller B, Fossa SD. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer. 2011;129:1225–1236. doi: 10.1002/ijc.26045.
    1. Touitou Y, Darbois Y, Bogdan A, Auzeby A, Keusseoglou S. Tumour marker antigens during menses and pregnancy. Br J Cancer. 1989;60:419–420. doi: 10.1038/bjc.1989.297.
    1. Schlageter MH, Larghero J, Cassinat B, Toubert ME, Borschneck C, Rain JD. Serum carcinoembryonic antigen, cancer antigen 125, cancer antigen 15-3, squamous cell carcinoma, and tumor-associated trypsin inhibitor concentrations during healthy pregnancy. Clin Chem. 1998;44:1995–1998.
    1. Botsis D, Sarandakou A, Kassanos D, Kontoravdis A, Rizos D, Protonotariou E, Phocas I, Creatsas G. Breast cancer markers during normal pregnancy. Anticancer Res. 1999;19:3539–3541.
    1. Cheli CD, Morris DL, Neaman IE, Dai J, Allard WJ, Yeung KK. Measurement of four tumor marker antigens in the sera of pregnant women. J Clin Lab Anal. 1999;13:35–39. doi: 10.1002/(SICI)1098-2825(1999)13:1<35::AID-JCLA7>;2-R.
    1. Bon GG, Kenemans P, Verstraeten AA, Go S, Philipi PA, van Kamp GJ, van Geijn HP, van Vugt JM. Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy. Fetal Diagn Ther. 2001;16:166–172. doi: 10.1159/000053903.
    1. Ercan S, Kaymaz O, Yucel N, Orcun A. Serum concentrations of CA 125, CA 15-3, CA 19-9 and CEA in normal pregnancy: a longitudinal study. Arch Gynecol Obstet. 2012;285:579–584. doi: 10.1007/s00404-011-2025-4.
    1. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC Jr. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol. 1984;64:703–707.
    1. Haga Y, Sakamoto K, Egami H, Yoshimura R, Akagi M. Evaluation of serum CA125 values in healthy individuals and pregnant women. Am J Med Sci. 1986;292:25–29. doi: 10.1097/00000441-198607000-00005.
    1. Jacobs IJ, Fay TN, Stabile I, Bridges JE, Oram DH, Grudzinskas JG. The distribution of CA 125 in the reproductive tract of pregnant and non-pregnant women. Br J Obstet Gynaecol. 1988;95:1190–1194. doi: 10.1111/j.1471-0528.1988.tb06798.x.
    1. Kobayashi F, Sagawa N, Nakamura K, Nonogaki M, Ban C, Fujii S, Mori T. Mechanism and clinical significance of elevated CA 125 levels in the sera of pregnant women. Am J Obstet Gynecol. 1989;160:563–566.
    1. Touitou Y, Bogdan A, Darbois Y. CA-125 ovarian cancer associated antigen in cancer and pregnancy: interpretation of enzyme immunoassay and immunoradiometric assay. Anticancer Res. 1989;9:1805–1807.
    1. Kenemans P, Bon GG, Kessler AC, Verstraeten AA, van Kamp GJ. Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125. Clin Chem. 1992;38:1466–1471.
    1. Spitzer M, Kaushal N, Benjamin F. Maternal CA-125 levels in pregnancy and the puerperium. J Reprod Med. 1998;43:387–392.
    1. Petraglia F, Luisi S, Benedetto C, Zonca M, Florio P, Casarosa E, Volpe A, Bernasconi S, Genazzani AR. Changes of dimeric inhibin B levels in maternal serum throughout healthy gestation and in women with gestational diseases. J Clin Endocrinol Metab. 1997;82:2991–2995. doi: 10.1210/jc.82.9.2991.
    1. Fowler PA, Evans LW, Groome NP, Templeton A, Knight PG. A longitudinal study of maternal serum inhibin-A, inhibin-B, activin-A, activin-AB, pro-alphaC and follistatin during pregnancy. Hum Reprod. 1998;13:3530–3536. doi: 10.1093/humrep/13.12.3530.
    1. Wallace EM, Riley SC, Crossley JA, Ritoe SC, Horne A, Shade M, Groome NP. Dimeric inhibins in amniotic fluid, maternal serum, and fetal serum in human pregnancy. J Clin Endocrinol Metab. 1997;82:218–222. doi: 10.1210/jc.82.1.218.
    1. La Marca A, Giulini S, Orvieto R, De L, Volpe A. Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod. 2005;20:1569–1572. doi: 10.1093/humrep/deh819.
    1. Nelson SM, Stewart F, Fleming R, Freeman DJ. Longitudinal assessment of antimullerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril. 2010;93:1356–1358. doi: 10.1016/j.fertnstert.2009.07.1676.
    1. Lutterodt M, Byskov AG, Skouby SO, Tabor A, Yding AC. Anti-Mullerian hormone in pregnant women in relation to other hormones, fetal sex and in circulation of second trimester fetuses. Reprod Biomed Online. 2009;18:694–699. doi: 10.1016/S1472-6483(10)60016-8.
    1. van Buul EJ, Steegers EA, Jongsma HW, Eskes TK, Thomas CM, Hein PR. Haematological and biochemical profile of uncomplicated pregnancy in nulliparous women; a longitudinal study. Neth J Med. 1995;46:73–85. doi: 10.1016/0300-2977(94)00104-H.
    1. He S, Bremme K, Kallner A, Blomback M. Increased concentrations of lactate dehydrogenase in pregnancy with preeclampsia: a predictor for the birth of small-for-gestational-age infants. Gynecol Obstet Invest. 1995;39:234–238. doi: 10.1159/000292417.
    1. Larsson A, Palm M, Hansson LO, Axelsson O. Reference values for clinical chemistry tests during normal pregnancy. BJOG. 2008;115:874–881. doi: 10.1111/j.1471-0528.2008.01709.x.
    1. Makkonen M, Penttila IM, Castren O. Serum lactic acid dehydrogenase and isoenzymes during pregnancy and labor. Acta Obstet Gynecol Scand. 1980;59:97–102. doi: 10.3109/00016348009154622.
    1. Fiegler P, Katz M, Kaminski K, Rudol G. Clinical value of a single serum CA-125 level in women with symptoms of imminent abortion during the first trimester of pregnancy. J Reprod Med. 2003;48:982–988.
    1. Abbassi-Ghanavati M, Greer LG, Cunningham FG. Pregnancy and laboratory studies: a reference table for clinicians. Obstet Gynecol. 2009;114:1326–1331. doi: 10.1097/AOG.0b013e3181c2bde8.
    1. Hayes DF, Zurawski VR Jr, Kufe DW. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol. 1986;4:1542–1550.
    1. Lelle RJ, Henkel E, Leinemann D, Goeschen K. Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest. 1989;27:137–142. doi: 10.1159/000293641.
    1. Tayyar M, Tutus A. The effect of maternal age, parity, and fetal sex on the amniotic fluid and maternal serum levels of CA 125, CA 19.9, CA 15.3, and CEA. Int J Fertil Womens Med. 1999;44:256–259.
    1. Kiran G, Kiran H, Guler FI, Ekerbicer HC, Kilinc M. Maternal serum and umbilical cord tumor marker levels at term pregnancy. Acta Obstet Gynecol Scand. 2005;84:85–89.
    1. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci. 2007;44:151–178. doi: 10.1080/10408360601003143.
    1. Shyu MK, Lin MC, Liu CH, Fu YR, Shih JC, Lee CN, Chen HY, Huang J, Huang MC, Hsieh FJ. MUC1 expression is increased during human placental development and suppresses trophoblast-like cell invasion in vitro. Biol Reprod. 2008;79:233–239. doi: 10.1095/biolreprod.108.067629.
    1. Scholz C, Hermann C, Kachler A, Kainer F, Friese K, Makrigiannakis A. et al.Association of placental inflammation with fetomaternal hemorrhage and loss of placental mucin-1. Arch Gynecol Obstet. 2012;285:605–612. doi: 10.1007/s00404-011-2028-1.
    1. Crombach G, Scharl A, Vierbuchen M, Wurz H, Bolte A. Detection of squamous cell carcinoma antigen in normal squamous epithelia and in squamous cell carcinomas of the uterine cervix. Cancer. 1989;63:1337–1342. doi: 10.1002/1097-0142(19890401)63:7<1337::AID-CNCR2820630719>;2-J.
    1. Sarandakou A, Kontoravdis A, Kontogeorgi Z, Rizos D, Phocas I. Expression of CEA, CA-125 and SCC antigen by biological fluids associated with pregnancy. Eur J Obstet Gynecol Reprod Biol. 1992;44:215–220. doi: 10.1016/0028-2243(92)90102-5.
    1. Takeshima N, Suminami Y, Takeda O, Abe H, Kato H. Origin of CA125 and SCC antigen in human amniotic fluid. Asia Oceania J Obstet Gynaecol. 1993;19:199–204.
    1. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998;13:179–187.
    1. Kobayashi F, Sagawa N, Nanbu Y, Nakamura K, Nonogaki M, Ban C, Fujii S, Mori T. Immunohistochemical localization and tissue levels of tumor-associated glycoproteins CA 125 and CA 19-9 in the decidua and fetal membranes at various gestational ages. Am J Obstet Gynecol. 1989;160:1232–1238.
    1. Aggarwal P, Kehoe S. Ovarian tumours in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol. 2011;155:119–124. doi: 10.1016/j.ejogrb.2010.11.023.
    1. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, van Holsbeke C, Savelli L, Fruscio R, Lissoni AA, Testa AC, Veldman J, Vergote I, Van Huffel S, Bourne T, Valentin L. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839. doi: 10.1136/bmj.c6839.
    1. Geerts I, Vergote I, Neven P, Billen J. The role of inhibins B and antimullerian hormone for diagnosis and follow-up of granulosa cell tumors. Int J Gynecol Cancer. 2009;19:847–855. doi: 10.1111/IGC.0b013e3181a702d1.
    1. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768–2773. doi: 10.1038/sj.onc.1205363.
    1. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–3700.
    1. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–408. doi: 10.1016/j.ygyno.2007.10.017.
    1. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, Timmerman D, De Moor B, Vergote I. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104:863–870. doi: 10.1038/sj.bjc.6606092.
    1. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, Setälä M, Härkki P, Jalkanen J, Fraser J, Mäkinen J, Auranen A, Poutanen M, Perheentupa A. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315–1319. doi: 10.1038/sj.bjc.6605011.
    1. Montz FJ, Horenstein J, Platt LD, d'Ablaing G, Schlaerth JB, Cunningham G. The diagnosis of immature teratoma by maternal serum alpha-fetoprotein screening. Obstet Gynecol. 1989;73:522–525.
    1. Wisser J, Florio I, Neff M, Konig V, Huch R, Huch A, von Mandach U. Changes in bone density and metabolism in pregnancy. Acta Obstet Gynecol Scand. 2005;84:349–354.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa